| HOME >> MEDICINE >> TECHNOLOGY |
ATLANTA, Feb. 4 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), http://www.geovax.com, an Atlanta based biotechnology company, announced the addition of company co-founder Dr. Harriet Robinson to its staff as Vice President of Research & Development. Dr. Robinson is known worldwide for her outstanding work on retrovirus biology and development of DNA vaccines with special emphasis on HIV/AIDS.
Significant advances by GeoVax's HIV/AIDS vaccine development program have warranted Dr. Robinson's full time participation. She has been instrumental in GeoVax's success through her HIV/AIDS vaccine development activities while at Emory University and as Chief Scientific Advisor to GeoVax. Dr. Robinson joined GeoVax part time in Nov. 2007 and will become full time Feb. 15, 2008.
By focusing her efforts exclusively at GeoVax, Dr. Robinson intends to speed up the vaccine development and human trial evaluation program required to meet FDA regulatory requirements and future vaccine commercialization efforts.
"Our AIDS vaccine efforts are rapidly moving forward to a new and exciting level and include plans for large Phase 2 human trials in 2008," Dr. Robinson said. "It's important for me to be at GeoVax full time to work with our excellent team in this important effort. It is my conviction that our AIDS vaccine is a prime candidate to be safe and effective in preventing AIDS."
"As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date," said Don Hildebrand, President, CEO, and Chairman of GeoVax Labs, Inc. "Her leadership in HIV/AIDS vaccine research is invaluable. We believe her contributions will positively impact the lives of millions of people worldwide."
About Dr. Harriet Robinson:
Dr. Robinson is the inventor of GeoVax's HIV-1 AIDS vaccine technology
and co-founder of GeoVax Labs, Inc. She served as Chi
'/>"/>
| SOURCE GeoVax Labs, Inc. Copyright©2008 PR Newswire. All rights reserved |